Skip to main content
PLOS One logoLink to PLOS One
. 2021 Sep 16;16(9):e0255708. doi: 10.1371/journal.pone.0255708

Identification of key genes and immune infiltration modulated by CPAP in obstructive sleep apnea by integrated bioinformatics analysis

Cheng Fan 1, Shiyuan Huang 1, Chunhua Xiang 1, Tianhui An 1, Yi Song 1,*
Editor: Giannicola Iannella2
PMCID: PMC8445487  PMID: 34529670

Abstract

Patients with obstructive sleep apnea (OSA) experience partial or complete upper airway collapses during sleep resulting in nocturnal hypoxia-normoxia cycling, and continuous positive airway pressure (CPAP) is the golden treatment for OSA. Nevertheless, the exact mechanisms of action, especially the transcriptome effect of CPAP on OSA patients, remain elusive. The goal of this study was to evaluate the longitudinal alterations in peripheral blood mononuclear cells transcriptome profiles of OSA patients in order to identify the hub gene and immune response. GSE133601 was downloaded from Gene Expression Omnibus (GEO). We identified black module via weighted gene co-expression network analysis (WGCNA), the genes in which were correlated significantly with the clinical trait of CPAP treatment. Finally, eleven hub genes (TRAV10, SNORA36A, RPL10, OBP2B, IGLV1-40, H2BC8, ESAM, DNASE1L3, CD22, ANK3, ACP3) were traced and used to construct a random forest model to predict therapeutic efficacy of CPAP in OSA with a good performance with AUC of 0.92. We further studied the immune cells infiltration in OSA patients with CIBERSORT, and monocytes were found to be related with the remission of OSA and partially correlated with the hub genes identified. In conclusion, these key genes and immune infiltration may be of great importance in the remission of OSA and related research of these genes may provide a new therapeutic target for OSA in the future.

Background

OSA is a highly prevalent sleep disorder, characterized by repetitive partial or complete airway collapse resulting in apneic events during sleep, sleep fragmentation and chronic intermittent hypoxia. The direct consequence of the intermittent hypoxia is an oxidative imbalance, with reactive oxygen species production, inflammatory cytokines (IL2, IL4, IL6), lipid peroxidation and cell-free DNA production [1], and patients with OSA have higher risk of developing metabolic comorbidities and cardiovascular disorders [24]. CPAP, as the first-choice common treatment for OSA, may exert various additional therapeutic benefits beyond its improvement of the oxygen supply. More specifically, CPAP treatment significantly changed the profile of endothelial function, improved blood flow in both macro- and microcirculation and lowered the inflammatory mediator level in a review conducted by Klaudia et al [5]. In addition, proper use of CPAP therapy provided significant benefits for the treatment of arrhythmia in patients with OSA [6]. However, CPAP is not to date the only possible treatment in patients with obstructive sleep apnea. CPAP treatment could fail in patients with lingual tonsil hypertrophy and transoral robotic surgery (TORS) could represent a valid therapeutic option for retrolingual airway collapse [7].

The etiology of OSA is not well established fundamentally, although several possible molecular mechanisms have been proposed. For instance, it was reported that early-morning after one night of intermittent hypoxemia-induced augmentation of DUSP1 gene expression could attenuated by CPAP treatment [8]. With the rapid development of microarray [9] and high-throughput gene sequencing technologies [10], gene expression-based disease biomarkers have attracted more and more attention. Previous studies had identified subcutaneous adipose tissue transcriptional pattern modulated in OSA and in response to its effective treatment of CPAP [11]. Nevertheless, reports about transcriptome in peripheral blood mononuclear cells affected by CPAP are limited. Because polysomnography (PSG) is expensive and time-consuming in clinical application, it is necessary to find cheap and convenient biomarker from venous blood for the therapeutic efficacy monitoring of CPAP intervention.

To identify the genes regulated by CPAP, we downloaded relevant dataset (GSE133601) from GEO and constructed weighted co-expression network by WGCNA method [12]. Key modules closely associated with CPAP therapy were identified. Functional enrichment analysis was further used to hint the biological function of the key module genes. Next, we identified hub genes by searching for common genes of differentially expressed genes (DEGs) and black module genes. Since CIBERSORT is a widely used analysis tool using microarray data or RNA-seq data to investigate the expression profile of 22 types of immune cells and to calculate the proportions of each type of immune cells in the samples [13], immune cells infiltration was evaluated in OSA patients via CIBERSORT. Furthermore, correlations between key genes and immune cells infiltration were calculated. To the best of our knowledge, this is the first study that integrated bioinformatics analyses are used to find key genes and immune infiltration characteristics among peripheral blood mononuclear cells modulated by CPAP in OSA patients.

Materials and methods

Data download and preprocessing

First, we researched with (“continuous positive airway pressure” or “CPAP”) and (“whole blood” or “peripheral blood”) and (“obstructive sleep apnea” or “OSA”) in GEO database to find the interested expression data. After excluding irrelevant datasets, the dataset of GSE133601 was included. In this gene expression study, 15 individuals of obstructive sleep apnea were treated with CPAP therapy (defined by at least 4 hours of CPAP use over the 3-month intervention period) participated. The GSE133601 contained 30 samples of peripheral blood mononuclear cells, which including pre and post treatment of CPAP. After the microarray data were downloaded successfully, it was transformed into gene expression information by the expression value of probes from the GEO dataset. Probes with more than one gene were eliminated and the average value was calculated for genes corresponding to more than one probe. Data analysis procedures for the whole study were illustrated in Fig 1.

Fig 1. Flow chart for the whole study.

Fig 1

Weighted gene co-expression network analysis (WGCNA)

Co-expression modules were constructed using 5,000 genes of high expression values by the “WGCNA” package [12] in R. Soft-thresholding parameter of β = 12 was selected to ensure a scale-free network, when the degree of independence was 0.8. The corresponding gene information for each module was extracted and the minimum number of genes was set as 50 to achieve high reliability of the results. The interaction of co-expression modules and module-trait relationship based on the eigengene were determined using R language [14] and the WGCNA algorithm. The heatmap tools package was used to analyze the strength of the interactions. The module with the first-ranked module significance (MS) was considered as the clinically significant modules.

Functional enrichment analysis

To investigate the function of the genes in clinically significant modules, the Gene Ontology (GO) annotation [15] and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses [16] were performed by DAVID database (https://david.ncifcrf.gov/). The GO functional analysis was divided into the following three parts: biological process (BP), molecular function (MF) and cell component (CC).

Identification of differentially expressed genes (DEGs) and common genes

A heat map was drawn to exhibit the expression difference between two groups of the top 200 DEGs with the “limma” package [17]. Common genes in both the black module and DEGs obtained in GSE133601 were identified using the VennDiagram package [18] in R.

Random forest

The random forest is a classification method that uses multiple trees to train and predict samples with high accuracy [19]. And it is a powerful tool for constructing a predictive model for new biomarkers, which was built via the randomForest package [20] in R software. It is less prone to over-fitting problems and can handle a large amount of noise. We used the common genes of the black module and DEGs as the classification feature, and pre and post CPAP samples as the variables. The samples in GSE133601 (n = 30) were randomly divided into the training set and test set with the ratio 2:1. The model built by the training set was tested by the test set. The error rate was calculated through Out-of-bag (OOB) [21] to evaluate the correct rate of the combined classification. The mean decrease accuracy (MDA) of the random forest model was positively correlated with the predictive variable, and the mean decrease Gini (MDG) was positively correlated with the most important variable [22]. Using pROC package [23], the value of area under the receiver-operator characteristics (ROC) curve (AUC) was used to validate the accuracy of the established model.

Evaluation of immune cell infiltration and its correlation with key genes

We assessed 22 types of immune cell using the CIBERSORT algorithm [13], including macrophages, T cells, natural killer (NK) cells, mast cells, B cells, dendritic cells (DC), monocytes, plasma cells, neutrophils, and eosinophils. After obtaining the expression matrix of immune cells according to the instruction of the CIBERSORT website, we use “ggplot2” package to draw boxplot to depict the distribution of immune cells. The Pearson correlation coefficient between each kind of immune cells was calculated and the results were displayed by correlation heatmap using “corrplot” package [24] in R software.

Results

Construction of weighted co-expression network and identification of key modules

Weighted co-expression network was constructed by WGCNA based on the GSE133601. In summary, a total of 15 samples with post CPAP therapy and 15 corresponding paired control samples of pre-treatment were included into the analysis. We chose β = 12 as the soft-thresholding parameter (Fig 2A). Then, cluster dendrogram (Fig 2B) and network heatmap plot (Fig 2C) were displayed. Correlation between different modules was visualized among the 13 modules. Meanwhile, based on the calculation of Pearson’s correlation coefficient, the black module which showed the highest MS (Fig 2D) was considered as the highest correlation one with the clinical trait of CPAP (cor = 0.31, p-value = 0.09) (Fig 2E). Finally, the black module, which contained 981 genes, was selected as a key module to be studied in following analysis.

Fig 2. Weighted correlation network analysis.

Fig 2

(A) Analysis of scale-free fit parameter and mean connectivity for various soft-thresholding powers. (B) Cluster dendrogram of genes, with dissimilarity based on topological overlap. (C) Co-expression similarity of entire modules based on hierarchical clustering of module eigengenes and the correlation between different modules. The color of cells in the heatmap represented the correlation coefficients of different sizes. Specifically, red colors stood for the positive correlations and blue colors represented the negative correlations. (D) Distribution of average gene significance and errors in the modules associated with the response to CPAP therapy. (E) Correlation heat map of gene modules and phenotypes. The figure without brackets in each cell indicated the clinical feature correlation coefficients. The corresponding p-value was shown below in parentheses. Red is positively correlated with the phenotype; green is negatively correlated with the phenotype.

Functional enrichment analysis of genes in the black module

The black module genes are mainly enriched in exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay (ontology: BP), cytoplasm (ontology: CC), and ubiquitin-protein transferase activity (ontology: MF). The top 15 GO enrichment analysis results are shown (Table 1). Based on KEGG pathway mapping, the black module genes are involved in 7 pathways, especially in RNA degradation significantly (P < 0.05). As is shown in Table 2.

Table 1. Top 15 GO enrichment terms associated with genes in black module.

Categray Top 15 enriched GO terms. Count P-value
BP GO:0043928~exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay 7 2.1E-3
GO:0007595~lactation 8 3.4E-3
GO:0051384~response to glucocorticoid 10 3.5E-3
GO:0045124~regulation of bone resorption 4 7.3E-3
GO:0001886~endothelial cell morphogenesis 4 1.3E-2
CC GO:0005737~cytoplasm 287 2.4E-4
GO:0005829~cytosol 191 4.7E-4
GO:0016607~nuclear speck 19 5.4E-3
GO:0043204~perikaryon 12 1.6E-2
GO:0042383~sarcolemma 10 1.7E-2
MF GO:0004842~ubiquitin-protein transferase activity 26 1.1E-2
GO:0051213~dioxygenase activity 5 1.5E-2
GO:0051920~peroxiredoxin activity 3 2.9E-2
GO:0005179~hormone activity 10 3.0E-2
GO:0005515~protein binding 435 3.1E-2

BP, biological process; MF, molecular function; CC, cell component.

Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of genes in black module.

Pathway ID Gene count P-value Genes
RNA degradation hsa03018 10 1.4E-2 PAN2, EDC4, LSM6, CNOT7, DIS3, CNOT2, PABPC3, DCPS, PFKP, EDC3
Neuroactive ligand-receptor interaction hsa04080 21 5.9E-2 UTS2R, LHCGR, OXTR, CALCRL, NPY5R, PTGER1, CHRNA4, MLNR, SCTR, LPAR1, TACR2, GRIK2, HTR5A, SSTR4, HCRTR2, RXFP2, P2RY8, HRH1, HRH3, LPAR6, TSHB
Sulfur metabolism hsa00920 3 7.0E-2 MPST, ETHE1, SUOX
Transcriptional misregulation in cancer hsa05202 14 7.2E-2 NGFR, CSF1R, CDKN1B, ITGAM, FUS, IL1R2, JMJD1C, MLF1, FOXO1, PTK2, SPINT1, TLX1, ITGB7, MET
Proteoglycans in cancer hsa05205 16 7.2E-2 ARHGEF12, PDPK1, SRC, LUM, ANK3, HIF1A, PTK2, ACTB, VEGFA, SMO, CTSL, TIMP3, ITGAV, PPP1R12B, MET, WNT2
Ubiquitin mediated proteolysis hsa04120 12 7.8E-2 UBE2W, CUL5, UBA7, AIRE, FBXW11, UBE2D2, SYVN1, UBA2, ANAPC4, KEAP1, STUB1, SKP1
Amino sugar and nucleotide sugar metabolism hsa00520 6 8.8E-2 CYB5R2, NAGK, GFPT2, GMPPA, PGM3, HK2

Identification of common hub genes

The top 200 differentially expressed genes (DEGs) were exhibited in a heat map, including top 100 up-regulated genes and top 100 down-regulated genes (Fig 3A). A total of 11 common hub genes (TRAV10, SNORA36A, RPL10, OBP2B, IGLV1-40, H2BC8, ESAM, DNASE1L3, CD22, ANK3, ACP3) were identified for further analysis, by application of the VennDiagram package in R (Fig 3B).

Fig 3. Identification of hub genes by intersection of black module genes and top 200 DEGs.

Fig 3

(A) Heat map of the top 200 DEGs. (B) Venn plot of common genes.

The random forest model of hub genes

The random forest regression classification model was constructed with 11 common hub genes. The false positive rate of the model fell to the lowest (about 34.49%), when mtry = 8 (Fig 4A). The error rate was almost stable, when the number of decision trees was about 500 (Fig 4B). Two indexes, mean decrease accuracy (the prediction error rate based on OOB) and mean decrease Gini (the Gini coefficient based on the sample fitting model), were calculated to measure the importance of variables. The results showed that OBP2B, IGLV1-40 and TRV10 were the more important variables (Fig 4C). We used the established model in the testing data sets to prove its high prediction cost. The diagnostic efficiency for testing set was 0.92 (Fig 4D). And the random forest model had a better value of AUC compared with all the single gene, in which OBP2B gene had the highest AUC of 0.813.

Fig 4. Construction of random forest model.

Fig 4

(A) The scatter plot of the false-positive rate. The vertical axis represents the false positive rate, and the horizontal axis represents mtry index (from 1 to 11). (B) Relationship between the related errors and the number of decision trees. The vertical axis represents the related errors, and the horizontal axis represents the number of decision trees. (C) The scatter plot of the random forest variable based on the index of mean decrease accuracy (the left panel) and mean decrease Gini (the right panel), respectively. (D) Evaluation of the prediction efficiency of the random forest model via ROC curve. Red line represents the random forest model, and green line represents OBP2B gene.

Immune cell infiltration results

We used the CIBERSORT algorithm to evaluate the association between CPAP phenotype and immune cells infiltration. The relative proportion of immune cell subtypes was displayed in the stacked barplot (Fig 5A) and boxplot (Fig 5B). The results showed that monocytes had the highest proportion and the number of monocytes in post-CPAP group was higher than control group (P<0.05), which suggested that monocytes were vital in OSA and the proportion of monocytes may be modulated by CPAP. However, there was no significant difference in the other 21 immune cells, let alone 5 kinds of immune cells with extremely low proportion (which were not shown). Finally, we found that CD4 naïve T cells, γδ T cells, naïve B cell, CD4 memory resting T cell and resting NK cells all had negative correlation with monocytes (Fig 5C) (P<0.05). Moreover, we had calculated the correlation between monocytes and 11 hub genes. TRAV10, SNORA36A, CD22 and ANK3 had negative correlation with monocytes (P<0.01), and DNASE1L3 and ACP3 had positive correlation with monocytes (P<0.01).

Fig 5. Evaluation and visualization of immune cell infiltration.

Fig 5

(A) Stacked barplot diagram of immune cell types of 30 samples in GSE133601. (B) Boxplot diagram of immune cells. (C) Correlation heat map of immune cells. Blue represents a positive correlation, red represents a negative correlation. The darker the color, the stronger the correlation.

Discussion

CPAP has become the first line therapy for OSA for a long time. In a meta-analysis of 35 trials, CPAP showed positive results in the apnea-hypopnea index (AHI) mean difference -33.8 events in an hour [25]. Other treatments are less common. For example, oral appliances are proven to be less effective than CPAP, especially in severe OSA [26]. Since traditional efficacy monitoring method PSG is expensive and time-consuming, the establishment of predictive biomarkers for OSA therapy response has become a priority. To investigate potential biomarkers for OSA therapy, gene expression data and network-based approaches were applied. The gene co-expression network was built via the WGCNA analysis method to identify key modules related to the clinical trait (CPAP treatment). We identified 981 genes in black module, which were significantly related to the interactions of target genes induced by CPAP therapy in patients with OSA. To the end, 11 hub genes were derived by intersection of black module genes and top 200 DEGs. Furthermore, random forest prediction model was constructed. ROC curve analysis indicated that the model had a good performance compared with single gene prediction. Finally, we explored the immune infiltration characteristics of OSA. Monocytes were found to be enriched in OSA, and could be elevated by CPAP therapy.

Part of the hub genes are involved in immune function obviously. Immunoglobulin Lambda Variable 1–40 (IGLV1-40) is a subtype of immunoglobulin light chains, and T cell receptor alpha variable 10 (TRAV10) is a subtype of T cell receptor (TR) alpha chain. V region of them participates in the antigen recognition [27]. CD22 is a receptor predominantly restricted to B cells and its main function is to inhibit BCR signaling [28]. However, direct proofs of closely relationship between the other genes and immunity are limited. For example, the ribosomal protein L10 (RPL10), also known as QM and DXS648, was firstly identified from human tumor cells as a tumor suppressor [29]. It belongs to a highly-conserved component of the large ribosomal subunit (60S) [30]. Odorant binding protein 2B (OBP2B) belongs to the lipocalin (LCN) family [31]. It played important roles in physiological processes by binding to and transporting small hydrophobic molecules including odorants, retinoids, steroid hormones, and lipids [32]. Meanwhile, there are no related reports whether these 11 hub genes can be used as therapeutic efficacy biomarkers of OSA.

It had been demonstrated that immune function played pivotal role in the development of OSA. Circulating monocytes [33] of OSA patients were activated and cytotoxic to endothelial cells. Specifically, monocytes in patients with OSA exhibited an immunosuppressive phenotype (high levels of HIF-1α, TGF-β, IL-10 and VEGF and decreased levels of IL-12p40), and CPAP treatment partially restored the impaired immune phenotype [34]. The results of CIBERSORT indicated that monocytes were enriched in OSA. Moreover, RPL10 and OBP2B had negative correlation with monocytes.

Nevertheless, the limitations of this study should also be clearly pointed out. Firstly, no direct experiments were performed to validate the prediction model of hub genes. Secondly, further proofs about the detailed molecular mechanisms are necessary. Finally, the small patient numbers and scant analytical methods may limit the predictive capability of the present model.

Conclusion

We identified 11 hub genes via integrated bioinformatics methods and constructed a random forest model with them to predict therapeutic efficacy of CPAP for OSA. This paper also indicated monocytes may be related with the remission of OSA. The mechanism between immune cells and these key genes may be of great importance in the remission of OSA and related research of these genes may provide a new therapeutic target for OSA in the future.

Data Availability

All relevant data are within the paper.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Maniaci A, Iannella G, Cocuzza S, Vicini C, Magliulo G, Ferlito S, et al. Oxidative Stress and Inflammation Biomarker Expression in Obstructive Sleep Apnea Patients. J Clin Med. 2021Jan13;10(2):277. doi: 10.3390/jcm10020277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Bonsignore MR, Borel AL, Machan E, Grunstein R. Sleep apnoea and metabolic dysfunction. Eur Respir Rev. 2013Sep1;22(129):353–64. doi: 10.1183/09059180.00003413 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Almendros I, Basoglu ÖK, Conde SV, Liguori C, Saaresranta T. Metabolic dysfunction in OSA: Is there something new under the sun? J Sleep Res. 2021Jun21:e13418. doi: 10.1111/jsr.13418 Epub ahead of print. . [DOI] [PubMed] [Google Scholar]
  • 4.Maher LLM, Coke LA. Diagnosis and treatment of obstructive sleep apnea and its impact on cardiovascular disease. J Am Assoc Nurse Pract. Epub 2021 Jun 23. doi: 10.1097/JXX.0000000000000632. [DOI] [PubMed] [Google Scholar]
  • 5.Brożyna-Tkaczyk K, Myśliński W, Mosiewicz J. The Assessment of Endothelial Dysfunction among OSA Patients after CPAP Treatment. Medicina (Kaunas). 2021Mar25;57(4):310. doi: 10.3390/medicina57040310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Wang XT, Zhao G, Tu L, Yue ZY, Liu ZH, Han J, et al. Continuous Positive Airway Pressure Effectively Alleviates Arrhythmias in Patients with Obstructive Sleep Apnea: Possible Relationship with Counteracting Oxidative Stress. Curr Med Sci. 2019Feb;39(1):52–58. doi: 10.1007/s11596-019-1999-1 . [DOI] [PubMed] [Google Scholar]
  • 7.Di Luca M, Iannella G, Montevecchi F, Magliulo G, De Vito A, Cocuzza S, et al. Use of the transoral robotic surgery to treat patients with recurrent lingual tonsillitis. Int J Med Robot. 2020Aug;16(4):e2106. doi: 10.1002/rcs.2106 Epub 2020 Apr 2. . [DOI] [PubMed] [Google Scholar]
  • 8.Hoffmann MS, Singh P, Wolk R, Narkiewicz K, Somers VK. Obstructive sleep apnea and intermittent hypoxia increase expression of dual specificity phosphatase 1. Atherosclerosis. 2013Dec;231(2):378–83. doi: 10.1016/j.atherosclerosis.2013.09.033 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Behzadi P, Ranjbar R. DNA microarray technology and bioinformatic web services. Acta Microbiol Immunol Hung. 2019Mar1;66(1):19–30. doi: 10.1556/030.65.2018.028 . [DOI] [PubMed] [Google Scholar]
  • 10.Nilsson RH, Anslan S, Bahram M, Wurzbacher C, Baldrian P, Tedersoo L. Mycobiome diversity: high-throughput sequencing and identification of fungi. Nat Rev Microbiol. 2019Jan;17(2):95–109. doi: 10.1038/s41579-018-0116-y . [DOI] [PubMed] [Google Scholar]
  • 11.Gharib SA, Hurley AL, Rosen MJ, Spilsbury JC, Schell AE, Mehra R, et al. Obstructive sleep apnea and CPAP therapy alter distinct transcriptional programs in subcutaneous fat tissue. Sleep. 2020Jun15;43(6):zsz314. doi: 10.1093/sleep/zsz314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008Dec29;9:559. doi: 10.1186/1471-2105-9-559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011Mar17;12:77. doi: 10.1186/1471-2105-12-77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Chan BKC. Data Analysis Using R Programming. Adv Exp Med Biol. 2018;1082:47–122. doi: 10.1007/978-3-319-93791-5_2 . [DOI] [PubMed] [Google Scholar]
  • 15.The Gene Ontology Consortium. The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res. 2019Jan8;47(D1):D330–D338. doi: 10.1093/nar/gky1055 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000Jan1;28(1):27–30. doi: 10.1093/nar/28.1.27 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015Apr20;43(7):e47. doi: 10.1093/nar/gkv007 Epub 2015 Jan 20. . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Chen H, Boutros PC. VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R. BMC Bioinformatics. 2011Jan26;12:35. doi: 10.1186/1471-2105-12-35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Speiser JL, Durkalski VL, Lee WM. Random forest classification of etiologies for an orphan disease. Stat Med. 2015Feb28;34(5):887–99. doi: 10.1002/sim.6351 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Rigatti SJ. Random Forest. J Insur Med. 2017;47(1):31–39. doi: 10.17849/insm-47-01-31-39.1 . [DOI] [PubMed] [Google Scholar]
  • 21.Degenhardt F, Seifert S, Szymczak S. Evaluation of variable selection methods for random forests and omics data sets. Brief Bioinform. 2019Mar22;20(2):492–503. doi: 10.1093/bib/bbx124 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Wang H, Yang F, Luo Z. An experimental study of the intrinsic stability of random forest variable importance measures. BMC Bioinformatics. 2016Feb3;17:60. doi: 10.1186/s12859-016-0900-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015May;12(5):453–7. doi: 10.1038/nmeth.3337 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Zhang H, Liu R, Sun L, Guo W, Ji X, Hu X. Comprehensive Analysis of Gene Expression Changes and Validation in Hepatocellular Carcinoma. Onco Targets Ther. 2021Feb15;14:1021–1031. doi: 10.2147/OTT.S294500 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Parsons C, Allen S, Parish J, Mookadam F, Mookadam M. The efficacy of continuous positive airway pressure therapy in reducing cardiovascular events in obstructive sleep apnea: a systematic review. Future Cardiol. 2017Jul;13(4):397–412. doi: 10.2217/fca-2017-0004 Epub 2017 Jun 20. . [DOI] [PubMed] [Google Scholar]
  • 26.Tserenpil G, Gebre M, Zergham AS, Sekhon AK, Malik BH. Managements for Obstructive Sleep Apnea in Adults: Review. Cureus. 2020Aug20;12(8):e9905. doi: 10.7759/cureus.9905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Lefranc MP. Immunoglobulin and T Cell Receptor Genes: IMGT(®) and the Birth and Rise of Immunoinformatics. Front Immunol. 2014Feb5;5:22. doi: 10.3389/fimmu.2014.00022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Jellusova J, Nitschke L. Regulation of B cell functions by the sialic acid-binding receptors siglec-G and CD22. Front Immunol. 2012Jan11;2:96. doi: 10.3389/fimmu.2011.00096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Dowdy SF, Lai KM, Weissman BE, Matsui Y, Hogan BL, Stanbridge EJ. The isolation and characterization of a novel cDNA demonstrating an altered mRNA level in nontumorigenic Wilms’ microcell hybrid cells. Nucleic Acids Res. 1991Oct25;19(20):5763–9. doi: 10.1093/nar/19.20.5763 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Loftus TM, Nguyen YH, Stanbridge EJ. The QM protein associates with ribosomes in the rough endoplasmic reticulum. Biochemistry. 1997Jul8;36(27):8224–30. doi: 10.1021/bi970288d . [DOI] [PubMed] [Google Scholar]
  • 31.Lacazette E, Gachon AM, Pitiot G. A novel human odorant-binding protein gene family resulting from genomic duplicons at 9q34: differential expression in the oral and genital spheres. Hum Mol Genet. 2000Jan22;9(2):289–301. doi: 10.1093/hmg/9.2.289 . [DOI] [PubMed] [Google Scholar]
  • 32.Charkoftaki G, Wang Y, McAndrews M, Bruford EA, Thompson DC, Vasiliou V, et al. Update on the human and mouse lipocalin (LCN) gene family, including evidence the mouse Mup cluster is result of an "evolutionary bloom". Hum Genomics. 2019Feb19;13(1):11. doi: 10.1186/s40246-019-0191-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med. 2002Apr1;165(7):934–9. doi: 10.1164/ajrccm.165.7.2104126 . [DOI] [PubMed] [Google Scholar]
  • 34.Hernández-Jiménez E, Cubillos-Zapata C, Toledano V, Pérez de Diego R, Fernández-Navarro I, Casitas R, et al. Monocytes inhibit NK activity via TGF-β in patients with obstructive sleep apnoea. Eur Respir J. 2017Jun15;49(6):1602456. doi: 10.1183/13993003.02456-2016. [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Giannicola Iannella

12 Aug 2021

PONE-D-21-23106

Identification of key genes and immune infiltration modulated by CPAP in Obstructive sleep apnea by integrated bioinformatics analysis

PLOS ONE

Dear Dr. Song,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 26 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Giannicola Iannella

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

"Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

4.Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. 

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Abstract

line 2, the sentencens are separated by a point. Please unify.

Background

- page 2, line 1, same of abstract line 2. Please unify the sentences.

- after line 1 add: The direct consequence of the intermittent hypoxia is an oxidative imbalance, with reactive oxygen species production, inflammatory cytokines (IL2, IL4, IL6), lipid peroxidation, and cell-free DNA production and please cite doi:10.3390/jcm10020277

- line 5, describe the findings of the study cited [5].

- line 7, add: however CPAP treatment could fail in patients with lingual tonsil hypertrophy and TORS could represent a valid therapeutic option for retrolingual airway collapse. please cite doi:10.1002/rcs.2106

- line ''Furthermore, immune cells infiltration was evaluated in OSA patients via CIBERSORT, and correlations between key genes and immune cells infiltration were calculated. '' Introduce first why you calculated immune infiltration and if there are studies that correlate it mention them in the text.

Materials and methods

describe the study design, year, protocol and cite a flow diagram to explain all the protocol with selection criteria.

Results

interesting and well written

Discussion

Line 1, cite papers on CPAP role in OSAS treatment discussing the main findings: doi:10.1007/s11325-014-1097-3

doi:10.1007/s11325-016-1419-8

- [11] please check the font

- '''Others have not been reported to have closely relationship with immunity.'' please cite the papers that states what you affirmed

Reviewer #2: The authors interestingly analyzed OSAS related genes correlating the outcomes with CPAP treatment. The paper has scientific soundness; however, minor corrections are required.

- English editing is necessary for both grammatic and punctuation (.And, patten, time‐ consuming);

Abstract

- before the sentence ''in conclusion.. report briefly the results found.

Background

- CPAP is not to date the only possible treatment in patients with obstructive sleep apnea. Different new technologies have been developed according to the profiles of the obstruction sites identified at Drug Induced Sleep Endoscopy, including different techniques from barbed wire pharyngoplasty up to robotic surgery in retrolingual collapses. Please cite doi: 10.1002 / rcs.2106 and doi: 10.1007 / s00405-020-05883-2

- please clarify the study protocol with a figure or a flowchart describing all the procedures performed;

Discussion

- cite references that support what stated in the sentence: ''The core genes of the clinically significant modules were supposed to be important in the remission of OSA''

the same with the sentence: '' Others have not been reported to have closely relationship with immunity. ...

- please read this review and modify the concept. In reality different biomarkers have been demonstrated in the literature: '' However, there are no related reports whether these genes can be used as therapeutic efficacy biomarkers of OSA. ''

- please read these metaanalysis and modify the concept. In reality different biomarkers have been demonstrated in the literature: '' However, there are no related reports whether these genes can be used as therapeutic efficacy biomarkers of OSA. ''

Imani MM, Sadeghi M, Khazaie H, Emami M, Sadeghi Bahmani D, Brand S. Evaluation of Serum and Plasma Interleukin-6 Levels in Obstructive Sleep Apnea Syndrome: A Meta-Analysis and Meta-Regression. Front Immunol. 2020 Jul 21; 11: 1343. doi: 10.3389 / fimmu.2020.01343. PMID: 32793188; PMCID: PMC7385225. and the paper

Rezaei F, Abbasi H, Sadeghi M, Imani MM. The effect of obstructive sleep apnea syndrome on serum S100B and NSE levels: a systematic review and meta-analysis of observational studies. BMC Pulm Med. 2020 Feb 5; 20 (1): 31. doi: 10.1186 / s12890-020-1063-8. PMID: 32024492; PMCID: PMC7003338.

- discuss at the end study's limitation

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

PLoS One. 2021 Sep 16;16(9):e0255708. doi: 10.1371/journal.pone.0255708.r002

Author response to Decision Letter 0


22 Aug 2021

Review 1

Comment: (Abstract) line 2, the sentences are separated by a point. Please unify.

Respond: Correction has been completed.

Comment: (Background) page 2, line 1, same of abstract line 2. Please unify the sentences. after line 1 add: The direct consequence of the intermittent hypoxia is an oxidative imbalance, with reactive oxygen species production, inflammatory cytokines (IL2, IL4, IL6), lipid peroxidation, and cell-free DNA production and please cite doi:10.3390/jcm10020277

Respond: Correction has been completed.

Comment: line 5, describe the findings of the study cited [5].

Respond: The study cited [5] is a review conducted by Klaudia et al. We have cited the results from the review to prove our opinion “CPAP may exert various additional therapeutic benefits beyond its improvement of the oxygen supply”.

Comment: line 7, add: however CPAP treatment could fail in patients with lingual tonsil hypertrophy and TORS could represent a valid therapeutic option for retrolingual airway collapse. please cite doi:10.1002/rcs.2106

Respond: Correction has been completed.

Comment: line ''Furthermore, immune cells infiltration was evaluated in OSA patients via CIBERSORT, and correlations between key genes and immune cells infiltration were calculated. '' Introduce first why you calculated immune infiltration and if there are studies that correlate it mention them in the text.

Respond: The reason why we calculated immune infiltration is that CIBERSORT is a widely used analysis tool using microarray data or RNA-seq data to investigate the expression profile of 22 types of immune cells and to calculate the proportions of each type of immune cells in the samples. We have already added the reason and cited related paper in the text.

Comment: (Materials and methods) describe the study design, year, protocol and cite a flow diagram to explain all the protocol with selection criteria.

Respond: Correction has been completed. A flow chart has been added as Fig1.

Comment: (Results) interesting and well written

Respond: Thanks for the comment.

Comment: (Discussion) Line 1, cite papers on CPAP role in OSAS treatment discussing the main findings: doi:10.1007/s11325-014-1097-3

doi:10.1007/s11325-016-1419-8

Respond: CPAP is one of the most effective therapies used in OSA. We have already cited related papers to prove it in revised manuscript.

Comment: [11] please check the font

Respond: Correction has been completed.

Comment: '''Others have not been reported to have closely relationship with immunity.'' please cite the papers that states what you affirmed

Respond: To be more accurate, direct proofs of closely relationship between the other genes and immunity are limited, compared with IGLV1-40, TRAV10 and TRAV10. Among 11 hub genes, IGLV1-40, TRAV10 and TRAV10 encode proteins which are part of immunoglobulin, T cell or B cell, so they have closely relationship with immunity obviously. However, proteins encoded by other 8 genes do not have direct relationship with immunity. At least, they are not part of the key proteins or cells involved in classic immunity pathway and reports about their roles in immunity are limited.

Reviewer 2

Comment: English editing is necessary for both grammatic and punctuation (.And, patten, time‐ consuming);

Respond: Corrections have been completed.

Comment: (Abstract) before the sentence ''in conclusion.. report briefly the results found.

Respond: The result is illustrated ''Eleven hub genes (TRAV10, SNORA36A, RPL10, OBP2B, IGLV1-40, H2BC8, ESAM, DNASE1L3, CD22, ANK3, ACP3) were traced and used to construct a random forest model to predict therapeutic efficacy of CPAP in OSA with a good performance with AUC of 0.92. Monocytes were found to be related with the remission of OSA and partially correlated with the hub genes identified''.

Comment: (Background) CPAP is not to date the only possible treatment in patients with obstructive sleep apnea. Different new technologies have been developed according to the profiles of the obstruction sites identified at Drug Induced Sleep Endoscopy, including different techniques from barbed wire pharyngoplasty up to robotic surgery in retrolingual collapses. Please cite doi: 10.1002 / rcs.2106 and doi: 10.1007 / s00405-020-05883-2

Respond: We have added related sentences at the end of the first paragraph in background. CPAP is not to date the only possible treatment in patients with obstructive sleep apnea. Other treatments (e.g. Surgery) could also be an option.

Comment: please clarify the study protocol with a figure or a flowchart describing all the procedures performed;

Respond: We have added a flow chart (Fig1) to describe the procedure of the study.

Comment: (Discussion) cite references that support what stated in the sentence: ''The core genes of the clinically significant modules were supposed to be important in the remission of OSA''. the same with the sentence: '' Others have not been reported to have closely relationship with immunity.

Respond: Sentences mentioned above are not expressed appropriately and we have corrected them.

1. ''The genes in key module were correlated significantly with the clinical trait of CPAP treatment''

2. ''Direct proofs of closely relationship between the other genes and immunity are limited, compared with IGLV1-40, TRAV10 and TRAV10''. Among 11 hub genes, IGLV1-40, TRAV10 and TRAV10 encode proteins which are part of immunoglobulin, T cell or B cell, so they have closely relationship with immunity obviously. However, proteins encoded by other 8 genes do not have direct relationship with immunity. At least, they are not part of the key proteins or cells involved in classic immunity pathway and reports about their roles in immunity are limited.

Comment: please read this review and modify the concept. In reality different biomarkers have been demonstrated in the literature: '' However, there are no related reports whether these genes can be used as therapeutic efficacy biomarkers of OSA. ''

Imani MM, Sadeghi M, Khazaie H, Emami M, Sadeghi Bahmani D, Brand S. Evaluation of Serum and Plasma Interleukin-6 Levels in Obstructive Sleep Apnea Syndrome: A Meta-Analysis and Meta-Regression. Front Immunol. 2020 Jul 21; 11: 1343. doi: 10.3389 / fimmu.2020.01343. PMID: 32793188; PMCID: PMC7385225. and the paper

Rezaei F, Abbasi H, Sadeghi M, Imani MM. The effect of obstructive sleep apnea syndrome on serum S100B and NSE levels: a systematic review and meta-analysis of observational studies. BMC Pulm Med. 2020 Feb 5; 20 (1): 31. doi: 10.1186 / s12890-020-1063-8. PMID: 32024492; PMCID: PMC7003338.

Respond: To be more accurate, there are no related reports whether these 11 hub genes can be used as therapeutic efficacy biomarkers of OSA. From papers cited by reviewer, we knew that IL-6, S100B and NSE were reported to be biomarker of OSA. However, we did not find related papers whether 11 hub genes (TRAV10, SNORA36A, RPL10, OBP2B, IGLV1-40, H2BC8, ESAM, DNASE1L3, CD22, ANK3, ACP3) can be used as therapeutic efficacy biomarkers of OSA

Comment: discuss at the end study's limitation

Respond: study's limitation was discussed at the end of discussion part.

''Nevertheless, the limitations of this study should also be clearly pointed out. Firstly, no direct experiments were performed to validate the prediction model of hub genes. Secondly, further proofs about the detailed molecular mechanisms are necessary. Finally, the small patient numbers and scant analytical methods may limit the predictive capability of the present model.''

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Giannicola Iannella

1 Sep 2021

Identification of key genes and immune infiltration modulated by CPAP in Obstructive sleep apnea by integrated bioinformatics analysis

PONE-D-21-23106R1

Dear Dr. Song,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

very interesting study.

The authors well replay to the comments of the reviewers. I believe that this paper is suitable of publication on PLOS ONE.

Best regards

Reviewers' comments:

-

Acceptance letter

Giannicola Iannella

8 Sep 2021

PONE-D-21-23106R1

Identification of key genes and immune infiltration modulated by CPAP in Obstructive sleep apnea by integrated bioinformatics analysis

Dear Dr. Song:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Giannicola Iannella

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the paper.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES